Economy/Home · Economy

Dong-A ST Rises for Second Consecutive Trading Day... Q3 Operating Profit Up 27.7%, Obesity Drug DA-1726 Clinical Results in Focus

Dong-A ST (170900) is extending its gains for a second consecutive trading day. The company's third-quarter operating profit rose 27.7% year-on-year, and the clinical trial results of its obesity drug candidate DA-1726 have emerged as a key variable going forward, drawing concentrated attention from

Wooil Shim
Staff Reporter
9 min read
Dong-A ST Rises for Second Consecutive Trading Day... Q3 Operating Profit Up 27.7%, Obesity Drug DA-1726 Clinical Results in Focus
CBC News

Dong-A ST (170900) is extending its gains for a second consecutive trading day. The company's third-quarter operating profit rose 27.7% year-on-year, and the clinical trial results of its obesity drug candidate DA-1726 have emerged as a key variable going forward, drawing concentrated attention from the securities industry.

On the 28th, Dong-A ST was trading at 34,950 won, up 50 won from the previous trading day (an increase of approximately 0.14%). The securities industry has cited the Q3 earnings improvement and the new drug development schedule as key monitoring points.

◆ Q3 Operating Profit Up 96.3% Quarter-on-Quarter... Profitability Improvement Stands Out

According to Samsung Securities' analysis, Dong-A ST's standalone Q3 revenue this year was 206.5 billion won, up 4.1% year-on-year, though down 0.6% compared to the previous quarter.

Operating profit came in at 21.4 billion won, up 27.7% year-on-year and up 96.3% from the previous quarter. Notably, the operating profit growth rate significantly outpaced the revenue growth rate.

Samsung Securities assessed that the profitability improvement was influenced by the growth of the ethical drug (ETC) business, centered on the gastroesophageal reflux disease treatment 'Motilitone' (Jakubo), along with the postponement of some R&D expenditure. The expansion of the ethical drug business combined with the change in the timing of expenses led to a larger increase in operating profit.

However, the deferral of R&D spending does not eliminate costs; it merely changes the timing of expenditure. Accordingly, quarterly profitability may vary depending on future R&D schedules, which should also be taken into consideration.

◆ Samsung Securities Maintains 'Buy' Rating... Target Price Lowered to 45,000 Won

Samsung Securities maintained its 'Buy' investment opinion on Dong-A ST while lowering its target price to 45,000 won. Compared to the current trading price of 34,950 won, this implies upside potential of approximately 28.8%. However, the target price reflects the securities firm's valuation of the company and does not guarantee an actual stock price increase.

Samsung Securities highlighted the company's core business growth through expanded sales of in-licensed products. The assessment is that a strengthened revenue base in the ethical drug segment can secure downside rigidity for the company's value.

◆ DA-1726 16-Week Clinical Data Within the Year, a Key Upcoming Momentum

In the new drug development area, the obesity drug candidate DA-1726 stands out as a major focus of interest. Data obtained from future clinical trials is expected to serve as a basis for judging its development competitiveness, and Samsung Securities forecast that DA-1726's 16-week clinical data, scheduled within the year, will become an important momentum going forward.

In the obesity drug market, not only weight-loss efficacy but also safety, tolerability, and dosing convenience are key evaluation factors. Depending on the clinical results, the development direction of the candidate and subsequent research strategies may also change. However, even if the clinical trial results are positive, subsequent development and approval procedures remain, making it difficult to prematurely conclude commercialization success.

◆ Short Term Hinges on Earnings Improvement, Mid-to-Long Term on New Drug Development

Dong-A ST is simultaneously pursuing two tasks: growth of its existing ethical drug business and new drug development. In the short term, the expansion of sales of in-licensed products including Motilitone and the trend of operating profit improvement are important, while in the mid-to-long term, the clinical results of DA-1726 could influence the company's valuation.

As Dong-A ST rises for a second consecutive trading day and trades at 34,950 won, market attention is focused on whether the ethical drug business can sustain its profitability and on the release of DA-1726's clinical data within the year.

[This article is intended to provide information for investment reference purposes and does not recommend the purchase or sale of any specific stock. Content may vary depending on market conditions. Investment decisions and the resulting responsibility rest with the investor. AI provided partial assistance.]

Wooil Shim
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.